Marizyme, Inc. (MRZM)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 19.23 Million USD | 46.28% |
| 2022 | 13.15 Million USD | 46.94% |
| 2021 | 8.95 Million USD | 50.73% |
| 2020 | 5.93 Million USD | 461.27% |
| 2019 | 1.05 Million USD | 327.94% |
| 2018 | 247.24 Thousand USD | 77.64% |
| 2017 | 139.17 Thousand USD | -47.39% |
| 2016 | 264.56 Thousand USD | -80.66% |
| 2015 | 1.36 Million USD | 11.55% |
| 2014 | 1.22 Million USD | -43.93% |
| 2013 | 2.18 Million USD | -90.23% |
| 2012 | 22.39 Million USD | 40.71% |
| 2011 | 15.91 Million USD | 57521.86% |
| 2010 | 27.62 Thousand USD | -45.78% |
| 2009 | 50.95 Thousand USD | -49.25% |
| 2008 | 100.4 Thousand USD | 259.09% |
| 2007 | 27.96 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.36 Million USD | 34.23% |
| 2024 Q1 | 1.18 Million USD | -85.07% |
| 2023 Q2 | 4.93 Million USD | 122.22% |
| 2023 Q3 | 4.98 Million USD | 0.98% |
| 2023 Q4 | 7.93 Million USD | 59.04% |
| 2023 Q1 | 2.22 Million USD | 0.5% |
| 2023 FY | 19.23 Million USD | 46.28% |
| 2022 FY | 13.15 Million USD | 46.94% |
| 2022 Q2 | 4.65 Million USD | 16.45% |
| 2022 Q1 | 3.99 Million USD | 34.64% |
| 2022 Q3 | 2.29 Million USD | -50.7% |
| 2022 Q4 | 2.21 Million USD | -3.58% |
| 2021 Q4 | 2.96 Million USD | 67.21% |
| 2021 FY | 8.95 Million USD | 50.73% |
| 2021 Q1 | 2.85 Million USD | -0.49% |
| 2021 Q2 | 2.49 Million USD | -12.46% |
| 2021 Q3 | 1.77 Million USD | -28.96% |
| 2020 Q1 | 471.37 Thousand USD | 93.58% |
| 2020 Q4 | 2.86 Million USD | 32.51% |
| 2020 Q3 | 2.16 Million USD | 397.65% |
| 2020 Q2 | 434.91 Thousand USD | -7.73% |
| 2020 FY | 5.93 Million USD | 461.27% |
| 2019 FY | 1.05 Million USD | 327.94% |
| 2019 Q4 | 243.49 Thousand USD | -52.12% |
| 2019 Q1 | 67.54 Thousand USD | 13.35% |
| 2019 Q2 | 237.36 Thousand USD | 251.41% |
| 2019 Q3 | 508.56 Thousand USD | 114.26% |
| 2018 Q3 | 70.62 Thousand USD | 6.53% |
| 2018 Q1 | 50.73 Thousand USD | -44.98% |
| 2018 FY | 247.24 Thousand USD | 77.64% |
| 2018 Q4 | 59.59 Thousand USD | -15.62% |
| 2018 Q2 | 66.29 Thousand USD | 30.67% |
| 2017 FY | 139.17 Thousand USD | -47.39% |
| 2017 Q3 | 7434.00 USD | -4.95% |
| 2017 Q4 | 92.21 Thousand USD | 1140.41% |
| 2017 Q2 | 7821.00 USD | 78.07% |
| 2017 Q1 | 4392.00 USD | -98.0% |
| 2016 FY | 264.56 Thousand USD | -80.66% |
| 2016 Q4 | 220 Thousand USD | 1000.06% |
| 2016 Q1 | 10 Thousand USD | 0.0% |
| 2016 Q3 | 19.99 Thousand USD | 200.0% |
| 2016 Q2 | -20 Thousand USD | -300.0% |
| 2015 FY | 1.36 Million USD | 11.55% |
| 2014 FY | 1.22 Million USD | -43.93% |
| 2013 Q3 | 3.29 Million USD | -6.87% |
| 2013 Q2 | 3.54 Million USD | -13.61% |
| 2013 Q1 | 4.1 Million USD | -35.65% |
| 2013 Q4 | -8.75 Million USD | -365.38% |
| 2013 FY | 2.18 Million USD | -90.23% |
| 2012 Q3 | 4.92 Million USD | -16.31% |
| 2012 FY | 22.39 Million USD | 40.71% |
| 2012 Q4 | 6.37 Million USD | 29.28% |
| 2012 Q2 | 5.89 Million USD | -4.44% |
| 2012 Q1 | 6.16 Million USD | 1.75% |
| 2011 Q2 | 5.36 Million USD | -65.8% |
| 2011 Q1 | 15.68 Million USD | 7968.85% |
| 2011 Q3 | 6.56 Million USD | 22.28% |
| 2011 FY | 15.91 Million USD | 57521.86% |
| 2011 Q4 | 6.05 Million USD | -7.67% |
| 2010 Q1 | 133.00 USD | -85.53% |
| 2010 FY | 27.62 Thousand USD | -45.78% |
| 2010 Q4 | 194.41 Thousand USD | 1103.8% |
| 2010 Q3 | 16.15 Thousand USD | -21.22% |
| 2010 Q2 | 20.5 Thousand USD | 15313.53% |
| 2009 FY | 50.95 Thousand USD | -49.25% |
| 2009 Q1 | 12.18 Thousand USD | 31.62% |
| 2009 Q2 | 10.18 Thousand USD | -16.42% |
| 2009 Q4 | 919.00 USD | -96.89% |
| 2009 Q3 | 29.59 Thousand USD | 190.69% |
| 2008 Q4 | 9255.00 USD | -56.17% |
| 2008 FY | 100.4 Thousand USD | 259.09% |
| 2008 Q1 | 24.04 Thousand USD | -25.82% |
| 2008 Q2 | 14.72 Thousand USD | -38.77% |
| 2008 Q3 | 21.11 Thousand USD | 43.42% |
| 2007 Q4 | 32.41 Thousand USD | 48.24% |
| 2007 Q1 | -10 Thousand USD | -200.0% |
| 2007 FY | 27.96 Thousand USD | 0.0% |
| 2007 Q2 | 21.66 Thousand USD | 316.67% |
| 2007 Q3 | 21.86 Thousand USD | 0.91% |
| 2006 Q4 | 10 Thousand USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1340.721% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -281.588% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 34.897% |
| Nascent Biotech, Inc. | 2.22 Million USD | -762.82% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2797.565% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 48.357% |
| Qrons Inc. | 643.67 Thousand USD | -2889.051% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4838.786% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 66.504% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4530.759% |
| Skye Bioscience, Inc. | 13.54 Million USD | -42.017% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 77.83% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -291.219% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -7251.135% |
| SQZ Biotechnologies Company | 85.61 Million USD | 77.529% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -559.749% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1181.034% |
| Mesoblast Limited | 5.9 Million USD | -225.988% |
| Genus plc | 147.7 Million USD | 86.974% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -119.152% |
| Pharming Group N.V. | 225.49 Million USD | 91.468% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -839.122% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1334.155% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -130.721% |
| ContraFect Corporation | 56.88 Million USD | 66.18% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -336.409% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1201.086% |
| IMV Inc. | 37.7 Million USD | 48.978% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -589.511% |
| MultiCell Technologies, Inc. | 567.42 USD | -3390656.759% |
| ONE Bio Corp. | 6.44 Million USD | -198.575% |
| Accustem Sciences Inc. | 3.74 Million USD | -413.553% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 77.614% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3516.768% |
| Q BioMed Inc. | 3.43 Million USD | -459.846% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 22.153% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -632.242% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1835.242% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 80.63% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -993.372% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -186.392% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -931.975% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 77059.328% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -20.172% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -948.438% |
| GB Sciences, Inc. | 1.42 Million USD | -1254.432% |
| Alpha Cognition Inc. | 9.7 Million USD | -98.234% |
| HST Global, Inc. | 140.9 Thousand USD | -13554.277% |
| CSL Limited | 3.44 Billion USD | 99.442% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1610.344% |
| Halberd Corporation | 74.84 Thousand USD | -25607.266% |
| Enzolytics Inc. | 2.17 Million USD | -782.761% |
| Agentix Corp. | 1.37 Million USD | -1302.57% |
| Resverlogix Corp. | 12.71 Million USD | -51.352% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -427.017% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.745% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1742.896% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -700.015% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1118.208% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -465.05% |
| AVAX Technologies, Inc. | 7.31 Million USD | -163.189% |
| Zenith Capital Corp. | 8.94 Million USD | -115.138% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.669% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -110340.457% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -683.599% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -11117.972% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -901.602% |
| Kadimastem Ltd | 2.41 Million USD | -698.296% |
| Helix BioMedix, Inc. | 1.97 Million USD | -875.634% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -77.048% |
| BioStem Technologies, Inc. | 22.97 Million USD | 16.257% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -10501.335% |
| LadRx Corporation | 3.81 Million USD | -404.745% |
| Cell Source, Inc. | 4.32 Million USD | -344.816% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1983.338% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1983.338% |
| NovAccess Global Inc. | 2.46 Million USD | -679.963% |
| Affymax, Inc. | 39.38 Million USD | 51.151% |
| Itoco Inc. | 919.14 Thousand USD | -1993.236% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -353.939% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1619.377% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3369.474% |
| CytoDyn Inc. | 18.05 Million USD | -6.545% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -76342.576% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -8642.279% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1255.116% |
| SYBLEU INC | 160.87 Thousand USD | -11859.417% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -959.275% |
| International Stem Cell Corporation | 5.27 Million USD | -265.013% |
| Bioxytran, Inc. | 3.82 Million USD | -403.641% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -36448.444% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -94477.162% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 46.948% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1089.112% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2514.694% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -518.445% |
| Neutra Corp. | 243.82 Thousand USD | -7790.966% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -10.213% |
| PureTech Health plc | 144.59 Million USD | 86.694% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 6.101% |
| IXICO plc | 4.7 Million USD | -308.749% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -118.709% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 83.66% |
| CSL Limited | 3.89 Billion USD | 99.506% |
| Cellectis S.A. | 97.32 Million USD | 80.23% |